NASDAQ:AVNR

(AVNR) (AVNR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AVNR stock logo

About (AVNR) Stock (NASDAQ:AVNR)

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA).

AVNR Stock News Headlines

5 Stocks Facing an Earnings Short Squeeze
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
5 Biotech Options to Buy Right Now
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Davenport PD warns of utility worker scam
8 Stocks Under $10 Moving Higher
See More Headlines
Receive AVNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (AVNR) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AVNR
CUSIP
05348P40
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

AVNR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of (AVNR) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (AVNR) investors own include Avid Bioservices (CDMO), (GTATQ) (GTATQ), Netflix (NFLX), Nokia Oyj (NOK), Alterity Therapeutics (PRAN), Ariad Pharmaceuticals (Aria), Alphabet (GOOG), Groupon (GRPN) and Intel (INTC).

This page (NASDAQ:AVNR) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners